Statins and the kidney

Current Opinion in Nephrology and Hypertension

Volumn 7, Issue 5, 1998, Pages 579-584

  Wheeler, David C ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATIN;

DRUG EFFECT; DYSLIPIDEMIA; HEART PROTECTION; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION;

EID: 0031670335     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199809000-00015     Document Type: Review

References (58)

1. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48:188-198.
2. Wheeler DC. Should hyperlipidaemia in dialysis patients be treated? Nephrol Dial Transplant 1997; 12:19-21.
3. Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994; 23:331-346.
4. Kobasigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63:331-338. An up-to-date review of the mechanisms, potential adverse effects and management of hypertipidaemia complicating heart, liver and kidney transplantation.
5. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53:363-373.
6. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348:1079-1082.
7. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343:425-430.
8. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993; 91:83-87.
9. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang X-M, Chia D, Ozawa M, et al. The effect of Pravastatin on acute rejection after kidney transplantation. A pilot study. Transplantation 1996; 61:1469-1474.
10. Attman P-O, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21:573-592.
11. Arnadottir M, Eriksson L-O, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin. Nephron 1993; 65:410-413.
12. Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993; 25:2732-2734.
13. Wheeler DC. Abnormalities of lipoprotein metabolism in CAPD patients. Kidney Int 1996; 50 (Suppl 56):S41-S46.
14. Jones P, Kafonek S, Laurora I, Hunninghake D for the CURVES investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol 1998; 81:582-587.
15. Stem RH, Yang BB, Norton M, Moore S, Abel RB, Olson SC. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmcol 1997; 37:816-819.
16. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995; 333:1301-1307.
17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
18. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996; 335:1001-1009.
19. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993; 72:1031-1037.
20. MAAS investigators. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344:633-638.
21. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. New Engl J Med 1993; 329:2002-2012.
22. Vita JA, Treasure CB, Yeung AC, Vekshtein VI, Fantasia GM, Fish RD, et al. Patients with evidence of coronary endothelial dysfuction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 1992; 85:1390-1397.
23. Ludmer PL, Selwyn AP, Shook TL Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315:1046-1051.
24. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81:491-497.
25. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients wild hypercholesterolemia. Circulation 1994; 89:2519-2524.
26. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95:324-328.
27. Haaber AB, Eidemak I, Jensen T, Feldt-Rasmussen B, Strandgaard S. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol 1995; 5:1581-1584.
28. Hand MF, Haynes WG, Johnstone HA, Anderton JL, Webb DJ. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995; 48:806-813.
29. Keidar S, Aviram M, Maor I, Oiknine J, Brook JG. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. Br J Clin Pharmacol 1994; 38:513-519.
30. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997; 128:11-18.
31. Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R, Bompiani G. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIb hyperlipoproteinemia. Curr Ther Res 1994; 55:1335-1344.
32. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92:3172-3177.
33. Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996; 122:225-233.
34. Rigatto C, Rush D, Perry Y, Walker S, Bose R, Bolli P. Cholesterol reduction in cyclosporine-treated renal transplant patients: effect on platelet-derived growth factor levels and platelet activation. Transplant Proc 1997; 29:2591-2592.
35. Keane WF, Kasiske BL, O'Donnell MP, Kim Y. Hypertension, hyperlipidemia, and renal damage. Am J Kidney Dis 1993; 21 (Suppl. 2):43-50.
36. Eddy AA, Liu E, McCulloch L. Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int 1996; 50:1139-1149.
37. Wheeler DC, Chana RS, Topley N, Petersen MM, Davies M, Williams JD. Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int 1994; 45:1628-1636.
38. Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 1993; 43:218-225.
39. Schreiner GF. Renal toxicity of albumin and other lipoproteins. Curr Opin Nephrol Hypertens 1995; 4:369-373.
40. Habenicht AJR, Glomset JA, Ross R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 1980; 255:5134-5140.
41. Quesney-Huneeus V, Galick HA, Siperstein MD, Erickson SK, Spencer TA, Nelson JA. The dual role of mevalonate in the cell cycle. J Biol Chem 1983; 258:378-385.
42. Quesney-Huneeus V, Wiley MH, Siperstein MD. Essential role for mevalonate synthesis in DNA replication. Proc Natl Acad Sci U S A 1979: 76:5056-5060.
43. Maltese WA. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 1990; 4:3319-3328.
44. Casey PJ, Solski PA, Der CJ, Buss JE. p21 ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 1989; 86:8323-8327.
45. Bassa BV, Roh DD, Kirschenbaum MA, Kamanna VS. Inhibition of mesangial cell cholesterol synthesis blocks PDGF-or serum-induced activation of Ras: protective role of mevalonic acid and farnesyl pyrophosphate [Abstract A1944]. J Am Soc Nephrol 1997; 8:420A.
46. Kim S-Y, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF. Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. Kidney Int 1995; 48:363-371.
47. Nogaki F, Muso E, Yashiro M, Sasayama S. Simvastatin suppresses the proliferation of cultured murine mesangial cells through PDGF suppression and matrix protein synthesis independent of TGF-β expression [Abstract A2429]. J Am Soc Nephrol 1997; 8:522A.
48. Samuelsson O, Mulec H, Knight-Gibson C, Attman P-O, Kron B, Larsson R, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12:1908-1915.
49. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia-a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 1994: 45 (Suppl 45):S125-S131.
50. Wheeler DC. Lipids - what is the evidence for their role in progressive renal disease? Nephrol Dial Transplant 1995; 10:14-16.
51. Lam KSL, Cheng IKP, Janus ED, Pang RWC. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38:604-609.
52. Nielsen S, Schmilz O, Møller N, Pørksen N, Klausen IC, Alberti KGMM, et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993; 36:1079-1086.
53. Hommel E, Andersen P, Gall M-A, Nielsen F, Jensen B, Rossing P, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992; 35:447-451.
54. Arnadottir M, Berg A-L. Treatment of hyperlipidemia in renal transplant recipients. Transplantation 1997; 63:339-345. An up-to-date review outlining the rationale for lipid-lowering therapy and examining the use of available agents including statins.
55. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. New Engl J Med 1995; 333:621-627.
56. Wenke K, Meiser B, Thiery J, Nagel D, von Scheldt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. A four-year randomized trial. Circulation 1997; 96:1398-1402.
57. Cutts JL, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibition ot 3-hydroxy-3-methylgtutaryl coenzyme A reductase by lovastatin. Int J Immunopharmacol 1989; 11:863-869.
58. Akhlaghi F, McLachlan AJ, Keogh AM, Brown KF. Effect of Simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 1997; 44:537-542.